Project Grant R01HL173038
Award Date
5/1/25
Completion Date
1/31/30
Dollars Obligated
$574K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $137,219 to the University of Illinois to support Dr. Santosh L. Saraf's research on sickle cell disease-related kidney disease. The key objectives are to: Investigate whether genetic variations in haptoglobin and heme oxygenase-1 predict chronic kidney dysfunction and its progression in sickle cell disease patients. Examine if complement...
The University of Illinois was awarded a $607,535 Project Grant by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant, with an award date of September 17, 2024 and ultimate completion date of August 31, 2025, will fund research to evaluate the effects of hemin, a breakdown product of cell-free hemoglobin, on the pulmonary endothelium and its role in the development of pulmonary hypertension and acute chest...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $637,526 to Duke University to conduct research on the effects of sickle cell disease (SCD) red blood cells (RBCs) on neutrophil activation and phenotypes. The research aims to systematically define the characteristics of sickle RBCs that cause neutrophil activation, and the resulting functional, phenotypic, and...
This Project Grant award, with an ID of R01HL173322, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The total funding amount is $1,449,454.00 and the award date is July 15, 2024, with an ultimate completion date of June 30, 2028. The overall goal of this grant is to characterize the role of Factor XII (FXII) in the thrombo-inflammatory complications of sickle cell disease (SCD), including...
The University of North Carolina at Chapel Hill received a $662,922 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) on June 15, 2024. The award will fund research to investigate the role of the RNA-binding protein YBX1 in regulating the transformation of cardiac fibroblasts into myofibroblasts as well as the reprogramming of cardiac fibroblasts into induced cardiomyocytes. The goal is to leverage these findings to reduce...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $213,284 to fund research on the regulation of endothelial hemoglobin alpha. The primary objective is to delineate the molecular mechanisms by which iron homeostasis in the endothelium modulates hemoglobin alpha expression and nitric oxide signaling, with potential implications for chronic cardiovascular diseases. The research...
The National Institutes of Health's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $200,000 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to the University of North Carolina at Chapel Hill. The grant will fund research to study the effect of NRF2 activation on vascular smooth muscle cell phenotype and assess a new local therapeutic approach that activates NRF2 in a mouse arteriovenous fistula (AVF) stenosis model....
The Department of Health and Human Services National Institutes of Health (NIH) awarded Duke University a $1,425,761 Project Grant under the Trans-NIH Research Support (CFDA 93.310) federal grant program. The purpose of this 3-year award is to harness stem cells and synthetic gene circuits to repair glomerular injury and address the significant burden of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) in the U.S. and worldwide. The research will leverage Duke's expertise in...
This $179,280 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the impact of early life nutritional stress on neutrophil development and function in sickle cell disease (SCD). The research aims to determine if there is a critical window during early life when nutritional exposures can modulate lifelong neutrophil levels and activity, and how this relates to SCD...
This $888,000 project grant from the National Heart, Lung and Blood Institute will fund research into the role of oxidative signaling through Na/K-ATPase in chronic kidney disease-induced anemia. The awardee, Marshall University Research Corporation, will investigate how accelerated red blood cell eryptosis, or premature cell death, contributes to anemia development and progression in chronic kidney disease. Two specific aims will be pursued: 1) defining the role of adipocytes and global...